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Imputation is a powerful statistical method that is distinct from the predictive modelling techniques more
commonly used in drug discovery. Imputation uses sparse experimental data in an incomplete dataset to
predict missing values by leveraging correlations between experimental assays. This contrasts with quanti-
tative structure–activity relationship methods that use only descriptor – assay correlations. We summarize
three recent imputation strategies – heterogeneous deep imputation, assay profile methods and matrix
factorization – and compare these with quantitative structure–activity relationship methods, including
deep learning, in drug discovery settings. We comment on the value added by imputation methods when
used in an ongoing project and find that imputation produces stronger models, earlier in the project, over
activity and absorption, distribution, metabolism and elimination end points.
Lay abstract: Imputation is the process of filling in the gaps in a dataset, where values have not yet
been measured, using the limited data that are already present. This may appear simple when only a few
values are missing but is challenging when more than half, or as much as 99% of the data are absent.
Data are a precious commodity for model building and using imputation enables greater value to be
extracted from the limited data available. This is particularly important in drug discovery, where the data
are especially sparse and noisy. The recent application of deep learning methods for data imputation has
led to significant advances in predictive power and unlocked hidden potential in drug discovery projects.
In this paper, we will discuss data imputation, compare it with other modeling methods and describe some
example applications in drug discovery.
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‘Imputation’ is a less-familiar term within statistics or machine learning in comparison with words such as ‘re-
gression’, ‘prediction’ and ‘classification’. In drug discovery, the latter three terms are commonly associated with
quantitative structure–activity relationship (QSAR) models, which attempt to describe a property of interest as a
mathematical function of some number of chemical ‘descriptors’ as inputs, to estimate the value of the property
for an as-yet unmeasured compound. This process is portrayed in the top half of Figure 1, where the properties
of interest could be biochemical or cell-based assay results, such as activities against protein targets, absorption,
distribution, metabolism or elimination (ADME) end points, or physicochemical properties such as solubility.
In contrast, imputation is the process of filling in the gaps in a dataset, where values have not yet been measured,
using the limited data that are already present. This process can be simple if only a handful of data points are
missing but is very challenging when more than half, or even 99% of the data are absent in the first instance.
Imputation is depicted in the bottom half of Figure 1, where not only descriptors are used as input to the model,
but also any of the sparse data points that have already measured in the assays of interest.
Data are precious commodities for model building, and the imputation process of expanding the data that are
available dramatically improves the quality of models. This not only captures correlation between descriptors and
assays, but also explicitly uses the experimental data as an input, which enables the model to learn directly from
Future Drug. Discov. FDD38 eISSN 2631-331610.4155/fdd-2020-0008 C© 2020 Optibrium Limited
Special Report Irwin, Mahmoud, Whitehead, Conduit & Segall
Descriptors
Descriptors
Assay data
Assays
C
om
po
un
ds
Imputed
assay data
QSAR
Imputation
Figure 1. A comparison of quantitative structure activity regression (top) for example a random forest model, with
imputation (bottom) for example the Alchemite™ deep imputation software.
QSAR: Quantitative structure–activity relationship.
assay–assay correlations [2,3]. This is particularly true in drug discovery, where the data are particularly sparse and
noisy [3]. Imputation models also provide the flexibility to use newly available experimental data to strengthen
predictions at any given time; as soon as a new data point is measured it can be input into the already-trained
model and used to enhance the quality of further predictions for unmeasured points. Furthermore, an important
requirement for successful application of models of any type is to identify when these values may be used with
confidence. The recent application of deep learning methods to data imputation, along with robust uncertainty
estimates, has addressed the challenge posed by spare and noisy data, led to advances in predictive power and
unlocked hidden potential in drug discovery projects, earlier than equivalent QSAR models [3].
Existing strategies for imputation
There are at least three noteworthy methods for imputation in drug discovery. These create interesting comparison
and are summarized below:
Heterogeneous deep imputation
Alchemite™ (Intellegens, Cambridge, UK) is a novel method which combines the power of deep learning with an
imputation framework and can exploit nonlinear correlations between heterogeneous assay end points [2,3]. Sparse
experimental data are input to the algorithm along with compound descriptors of any type. An initial best guess of
the missing values is used, the full matrix is then reinserted into the algorithm and this process is repeated until the
algorithm converges [4]. This method is one of the few that provide an uncertainty estimate for outputs by using an
ensemble of predictions in the form of a distribution. This allows one to focus on the most confident and reliable
results [2,3] and avoid missed opportunities [5].
Assay profile methods
Profile QSAR (pQSAR) is a two-step imputation method formed from combination of commonly used QSAR
approaches. pQSAR first builds a layer of random forest models [1], then subsequently uses a linear model to look
for assay–assay correlations from the individual predictions of the initial models [6]. So far, this method has focused
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Figure 2. Performance in root-mean-square error measured on the independent test set of the Novartis benchmark
‘realistic’ split for three imputation models, random forest and deep neural network prediction models, and the
Alchemite™ virtual model (where Alchemite runs as a prediction model with no input experimental data). This
illustrates improvement in prediction quality (reduction in root-mean-square error) as the methods which provide
uncertainty estimates alongside predictions focus on the most confident fraction of the dataset to impute/predict.
CMF: Collective matrix factorization; DNN: Deep neural network; pQSAR: Profile quantitative structure–activity
relationship; RMSE: Root-mean-square error.
on homogeneous datasets comprised of activity from a class of proteins, for example kinases and GPCRs, to use
the linear correlations between the activities in related proteins [7].
Bayesian matrix factorization
The Macau method combines Bayesian probabilistic inference with an implementation of matrix factorization [8].
This method also takes chemical descriptors as an input, the authors refer to this as ‘high dimensional side
information’. This method can handle data sets with millions of compounds and tens of millions of data points.
It is inherently a linear method which may struggle with virtual compound predictions due to empty rows and
columns.
Figure 2 shows a comparison of imputation and QSAR methods on a benchmarking dataset published by
Novartis (Basel, Switzerland) [6], which was designed to be realistic in that the test set required extrapolation from
training data. This comparison builds on that of Whitehead et al. [2], including the latest version of the Alchemite
deep imputation method [2,3], pQSAR 2.0 [7], collective matrix factorization [9], a precursor the Macau Bayesian
matrix factorization method [8], and QSAR models using random forests [1] and a multi-target deep neural network
using Google Brain’s TensorFlow software [10].
Figure 2 shows the advantages of choosing an imputation method. When considering the full test set, Alchemite
and pQSAR 2.0 provide the most accurate results; the lowest root-mean-square error values, which are much
lower than the other methods. For methods which provide uncertainty estimates on their predictions (Alchemite
and random forest) we can focus on the predictions with the greatest confidence, resulting in a reduction in
root-mean-square error for these results.
The combination of imputation and effective confidence estimates mean that scientist can choose an appropriate
level of uncertainty and partially fill in the dataset with sufficiently high-quality predictions.
Virtual models
An important application of QSAR models is to make predictions for ‘virtual compounds’ which have not yet been
synthesized and thus have no experimental information, based solely on molecular descriptors. Deep imputation
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Figure 3. Example of the virtual model, compounds are trained on assay data from the training set (green squares)
and no assay data are provided at test time to generate virtual predictions for all assays (purple squares).
models can easily be extended to this case by only inputting the compound descriptors for new compounds, as
illustrated in Figure 3.
With no existing experimental data, the algorithm has the same information as a QSAR method at test time;
however, the model can still exploit assay–assay correlations it learned in training and use these to enhance
predictions. We would expect the model performance to therefore lie between a good QSAR method and the
case of an imputation model with experimental information. Figure 2 shows this additional case labeled ‘Virtual
compound Alchemite’. In the limit of predicting 100% of the data, the performance is comparable with a multi-
target deep neural network, but the ability for Alchemite to produce an uncertainty estimate means the most
confident predictions can be determined. This model clearly outperforms a random forest model with uncertainties
derived from the ensemble of decision trees.
Practical application of imputation
There is an evidence that imputation adds value to drug discovery projects beyond the benchmarking data discussed
above. An illustrative case study demonstrated successful application of deep imputation to heterogeneous drug
discovery project data [3]. Remarkably, fewer data points than expected were needed to leverage the power of deep
learning to assist in the prediction of actives. While standard deep learning models are notorious for requiring big
data to be effective, the deep imputation models made confident predictions on typical project activity and ADME
data – on the order of tens to hundreds of compounds [3]. The imputation models had an average coefficient of
determination, R2 = 0.72, where the best QSAR equivalents achieved R2 = 0.50. It was also found that QSAR
models completely failed to predict a cell-based activity end point, achieving a negative R 2, whereas the imputation
method could make accurate predictions, R2 = 0.66, by exploiting assay–assay correlations [3].
Further to that study, the value added as a project progresses is illustrated in Figure 4 by iteratively training
Alchemite models on time-ordered project data, including both activity and ADME columns. Alchemite consistently
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Figure 4. A performance metric across a project for a mixture of 15 drug discovery activities and absorption,
distribution, metabolism or elimination end points. The percentage of end points with R2 values above 0.5 (light), 0.6
and 0.7 (dark) is plotted against number of data points used to construct the model for both Alchemite™ deep
imputation and random forest models.
outperforms random forest models. The percentage of Alchemite end points with model R2 > 0.6 rises steadily,
even for low numbers of training points, whereas random forest only shows a significant rise for more than 600
measured data points. On low quantities of data points, 20–30% of Alchemite end points have excellent models
R2 > 0.7, whereas random forest models cannot achieve this level of accuracy, even when using all of the data.
Therefore, fewer data points are needed to build high quality imputation models, equating to fewer experiments,
reduced cost and a shorter timeframe.
Conclusion
We have explained the concept of imputation and contrasted it with standard QSAR models. Imputation uses the
known data explicitly to reconstruct the missing elements allowing assay–assay correlations and thereby gains more
value from the investment in experimental measurements. One immediate and obvious advantage with imputation
is the filling of the entire data matrix, which can provide as much as 100-times the original data.
Although a new method in the field of drug discovery, there is growing evidence that it can make more effective
and efficient use of data in a variety of applications, to improve productivity and efficiency.
Future perspective
Imputation uses existing data resources more efficiently. An obvious application is for imputation to be used at the
data source itself, whether that be a local dataset, corporate repository or large-scale data warehouse. Filling in the
gaps in data sources with confident predictions will dramatically increase the wealth of information that can be
mined to identify high-quality compounds. A combination of proprietary data combined with all known public
domain data in a single imputed database will also give stronger predictive models for many types of end points in
the chemical and biological domain.
Imputation can be used for combination of diverse types of sparse data, not only from experiments, but also
computational simulations and physics-based calculations. Data can be aggregated across different resolutions and
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scales, with inexpensive and fast calculations assisting the prediction of moderately challenging end points which
in turn assist the prediction of the hardest, slowest and most expensive data points to collect.
Any imputation method that can fulfill this would need to be proven to handle very sparse, noisy and heteroge-
neous data, scale to large sizes and remain robust to unrelated data sources being merged. The strongest method
so far is the deep imputation method that provides uncertainty estimates in each imputed value. The flexibility
of the deep learning framework will facilitate applications for novel kinds of data including time series, curve and
distributional data, text data, aggregations of samples among populations and even graphical and network-based
data sources.
For drug discovery, the combination of chemist and computational algorithm will enhance productivity, taking
the burden of routine and intensive tasks away from the expert leaving them more freedom to be creative and
focused on the human strategy elements of the design process. Imputation methods will take a leading role in
achieving this goal as a foundation for further downstream AI and machine learning methods, which cannot handle
incomplete data. Such algorithms could make additional statements about missing values beyond ‘what number
can I assign to this missing value?’ and ‘how confident are we in this prediction?’; we could ask questions such as
‘how relevant is this missing value to my project?’, ‘which experiment should I perform next?’ and ‘can I trust this
data point or should I remeasure it?’. Addressing these questions will ultimately assist a step change in efficiency
and effective resource allocation.
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